Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 20/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.81 |
| ▸ | CIT | O14578 | 5/20 | 0.81 |
| ▸ | BMP2K | Q9NSY1 | 5/20 | 0.81 |
| ▸ | GAK | O14976 | 4/20 | 0.81 |
| ▸ | MYLK2 | Q9H1R3 | 3/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.81 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.81 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.81 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.81 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.68 |
| ▸ | PRKCB | P05771 | 1/20 | 0.68 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | PRKG2 | Q13237 | 2/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.67 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.67 |
| ▸ | GSK3A | P49840 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17155290 | 1.00 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK | |
| SCHEMBL30061274 | 1.00 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK | |
| SCHEMBL31338821 | 0.89 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK | |
| SCHEMBL17155473 | 0.89 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK | |
| SCHEMBL30059580 | 0.89 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK | |
| SCHEMBL17143384 | 0.89 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK | |
| SCHEMBL17144091 | 0.89 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK | |
| SCHEMBL19901204 | 0.88 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK | |
| SCHEMBL30059555 | 0.88 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK | |
| SCHEMBL17143784 | 0.88 | AAK1 (1.00) | AAK1MKNK1CITBMP2KGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277001-A1 | BIARYL KINASE INHIBITORS | Cosmic Pet LLC | 2021-09-09 | — | — | US | disclosed |
| CN-112142655-A | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-108368084-B | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10351563-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190048006-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-02-14 | — | — | US | disclosed |
| EP-3126351-A1 | BIARYL KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015153720-A1 | BIARYL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277001-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | AAK1 1/4885MKNK1 37/4885CIT 961/4885 |
| US-20190048006-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | AAK1 1/4885MKNK1 37/4885CIT 961/4885 |
| US-10351563-B2 | Biaryl kinase inhibitors | AAK1, NCK1, MARCKS | AAK1 1/4885MKNK1 37/4885CIT 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.